Novartis Restructure Sees Drug Development And Oncology Chiefs Exit
Aims To Boost R&D And Commercial Performance
Executive Summary
Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.
You may also be interested in...
Novartis Flies The Flag For US Despite More Job Cuts
It is still “a priority country,” the Switzerland-based giant tells Scrip, as around 240 jobs face the axe at Novartis’s development organizational unit across the Atlantic.
Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
Novartis Boosts Biologics Offering With $300m Investment In European Facilities
The funds will help advance biologic R&D, manufacturing and commercialization capabilities across Europe as the major pursues more sophisticated modalities, its global biologics head tells Scrip.